ArticleJournal of clinical practice and research2026
The Effect of Myeloid-Derived Suppressor Cells in Graft-versus-Host Disease.
Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Myeloid-derived suppressor cells (MDSCs) are immature myeloid progenitors, including monocytic and granulocytic subgroups (M-MDSCs and PMN-MDSCs). They exhibit immunoregulatory and immunosuppressive properties by limiting immune-mediated pathology and protecting the host from destructive inflammatory damage. Graft-versus-host disease (GVHD) comprises a series of immune-mediated inflammatory events in which donor-derived T cells target the tissues and organs of the transplant recipient. This study aims to evaluate the behavior of MDSCs during GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Materials and Methods: Fifteen patients who underwent allogeneic HSCT were included in the study. MDSCs and their subsets were identified and characterized by flow cytometry on days 0, 30, 60, and 90 post-engraftment. Results: The median frequency of monocytic MDSCs (M-MDSCs) on the first day of engraftment was significantly higher in patients without GVHD than in those who developed GVHD. Furthermore, the expansion of M-MDSCs occurred significantly earlier than that of the other MDSC subset. Conclusion: Monocytic MDSCs play a key regulatory role in limiting GVHD and may serve as potential therapeutic targets for GVHD prevention or treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.